Last reviewed · How we verify
NCT03821792
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
Phase 2 trial testing Abiraterone Acetate in Metastatic Prostate Carcinoma in 60 participants. Participants enrolled and being followed up; not accepting new ones.
11 October 2026
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 22 July 2019 |
| Primary completion | 11 October 2026 |
| Estimated completion | 11 October 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Abiraterone Acetate (ABIRATERONE) — full drug profile →
- Apalutamide (apalutamide) — full drug profile →
- Prednisone (prednisone) — full drug profile →
Conditions studied
- Metastatic Prostate Carcinoma — all drugs for Metastatic Prostate Carcinoma →
- Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →
- Prostate Carcinoma Metastatic in the Bone — all drugs for Prostate Carcinoma Metastatic in the Bone →
- Stage IV Prostate Cancer AJCC v8 — all drugs for Stage IV Prostate Cancer AJCC v8 →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, male only, with Metastatic Prostate Carcinoma or Prostate Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well abiraterone acetate, prednisone, and apalutamide work in treating patients with hormone-naive prostate cancer that has spread to other places in the body. Androgen can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate and apalutamide may lessen the amount of androgen made by the body.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evolving Treatments and Resistance Mechanisms in Prostate Cancer Therapeutics.
Sai Rishma Reddy GSV, Kumar A, Sharma NK, Samanta K, et al · · 2026 · PMID 41988377 · DOI 10.1021/acsptsci.5c00757
Verify or expand the search:
- PubMed search for NCT03821792
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Abiraterone Acetate
Trials testing the same drug.
- NCT06632977 — Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial · Phase 2 · recruiting
- NCT06650579 — REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial · Phase 3 · recruiting
- NCT06369610 — Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer · Phase 2 · recruiting
- NCT06120491 — Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice · Phase 3 · recruiting
- NCT04879589 — Phase 1 Study of ATRS-2002 in Healthy Male Adults · Phase 1 · withdrawn
Other recruiting trials for Metastatic Prostate Carcinoma
Currently open trials in the same condition.
- NCT07073794 — Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recu · Phase 2 · recruiting
- NCT06305598 — Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration · Phase 1 · recruiting
- NCT05805371 — PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resist · Phase 1 · recruiting
- NCT05869682 — Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Underg · Phase 2 · recruiting
- NCT05627219 — Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network · recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03821792 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03821792.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing